BLAIRE BLANKINSHIP: Open Payments
NPI 1124577580 · ENID, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,137 in 56 payments from 12 companies in 2025. Trend: 2023 $633 · 2024 $507 · 2025 $1,137
Food & beverage: $1,137
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 18 | $360 |
| Regeneron Healthcare Solutions, Inc. | 10 | $205 |
| GlaxoSmithKline, LLC. | 8 | $160 |
| GENZYME CORPORATION | 4 | $107 |
| Novartis Pharmaceuticals Corporation | 3 | $62 |
| AstraZeneca Pharmaceuticals LP | 3 | $59 |
| Amgen Inc. | 3 | $56 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $30 |
| BioCryst US Sales Co., LLC | 1 | $26 |
Products named: Hizentra, DUPIXENT, NUCALA, FASENRA, TEZSPIRE, Rhapsido, NEFFY, Haegarda.
Industry payments across OK — which companies pay providers there.
